Pathos AI was founded in 2022 to apply an AI-first, data-rich approach to the slow and failure-prone process of developing cancer drugs. The company was co-founded by Eric Lefkofsky, also the founder of Tempus, and Ryan Fukushima, drawing on deep experience at the intersection of healthcare data and oncology. Pathos's thesis is that combining vast amounts of real-world clinical and molecular cancer data with modern machine learning can dramatically improve the odds and speed of bringing precision oncology therapeutics to patients.
Unlike platform-only AI drug discovery companies, Pathos operates as a full drug development company, advancing its own clinical-stage pipeline. Its AI platform informs target selection, patient stratification, and trial design, helping to de-risk programs before and during clinical development. This integrated model, owning both the AI engine and the therapeutic assets, aligns the company's economics with clinical success rather than software licensing alone.
Pathos has built momentum quickly. In 2025 it announced a partnership to advance a Novo Nordisk solid tumor drug and appointed biotech veteran Iker Huerga as CEO to lead its next phase of AI-enabled drug development. The combination of proprietary data, an experienced team, and a partnered pipeline distinguishes Pathos in a competitive field.
The company's funding trajectory has been steep. In October 2024 it closed an oversubscribed $62 million Series C led by NEA, with participation from Revolution Growth and existing insiders, at a $600 million valuation. Then in May 2025, Pathos announced a $365 million Series D that pushed its post-money valuation to approximately $1.6 billion, with prior backers including NEA and General Atlantic. The capital funds team expansion, platform development, and advancement of its clinical pipeline.
With its data advantage, marquee founder, and well-capitalized balance sheet, Pathos AI is positioned as one of the more ambitious players attempting to fuse AI with end-to-end oncology drug development.